OBJECTIVE: To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ). METHODS: The case records of women (n = 33) exposed to HCQ during their pregnancies (n = 36) and of 53 control patients from a single lupus pregnancy centre were reviewed to determine lupus activity, obstetric experience, and infant outcome. RESULTS: HCQ was not apparently teratogenic. Lupus activity and obstetric outcome in the two groups were similar. CONCLUSION: HCQ continuation is probably safe during pregnancy in patients with lupus, but there is no obvious advantage in commencing treatment.
OBJECTIVE: To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ). METHODS: The case records of women (n = 33) exposed to HCQ during their pregnancies (n = 36) and of 53 control patients from a single lupus pregnancy centre were reviewed to determine lupus activity, obstetric experience, and infant outcome. RESULTS:HCQ was not apparently teratogenic. Lupus activity and obstetric outcome in the two groups were similar. CONCLUSION:HCQ continuation is probably safe during pregnancy in patients with lupus, but there is no obvious advantage in commencing treatment.
Authors: Fokaline Vroom; Hermien E K de Walle; Mart A J F van de Laar; Jacobus R B J Brouwers; Lolkje T W de Jong-van den Berg Journal: Drug Saf Date: 2006 Impact factor: 5.606
Authors: Christina Chambers; Gideon Koren; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones Journal: Can Fam Physician Date: 2007-03 Impact factor: 3.275
Authors: Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli Journal: Nat Rev Rheumatol Date: 2012-07-17 Impact factor: 20.543